Tsuda Hiroyuki, Kotani Tomomi, Sumigama Seiji, Mano Yukio, Hayakawa Hiromi, Kikkawa Fumitaka
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Nagoya, Japan.
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Nagoya, Japan.
Taiwan J Obstet Gynecol. 2016 Feb;55(1):26-9. doi: 10.1016/j.tjog.2015.12.003.
Constipation is common and a significant problem in pregnant women. The purpose of this study was to examine the efficacy and the safety of daikenchuto in pregnant women with constipation.
This was a prospective study, and a total of 20 patients were registered between February 2010 and August 2012. The patients received 7.5 g/d of daikenchuto for 28 days from the day of registration. All enrolled patients were asked to complete the constipation assessment scale (CAS) every day. In addition, we measured the aspartate transaminase, alanine transaminase, blood urea nitrogen, and creatinine levels to assess the adverse effects of daikenchuto.
The CAS scores were significantly lower at 28 days after daikenchuto treatment (p = 0.019), with a significant effect achieved on Day 1. The impact of the therapy was greatest in the second trimester (p = 0.043). No significant adverse effects of daikenchuto were observed, and the rates of preterm birth and pregnancy-induced hypertension were 10% and 5%, respectively, which are similar to previously reported values.
We herein demonstrated the efficacy and safety of daikenchuto in pregnant women with constipation. We hope that our findings will aid in the management of constipation in pregnant women.
便秘在孕妇中很常见且是一个重要问题。本研究的目的是探讨大建中汤对便秘孕妇的疗效和安全性。
这是一项前瞻性研究，2010年2月至2012年8月共登记了20例患者。患者从登记之日起接受7.5克/天的大建中汤，持续28天。所有入选患者每天都被要求完成便秘评估量表（CAS）。此外，我们测量了天冬氨酸转氨酶、丙氨酸转氨酶、血尿素氮和肌酐水平，以评估大建中汤的不良反应。
大建中汤治疗28天后，CAS评分显著降低（p = 0.019），第1天即取得显著效果。该疗法在孕中期的影响最大（p = 0.043）。未观察到大建中汤有明显的不良反应，早产率和妊娠高血压率分别为10%和5%，与先前报道的值相似。
我们在此证明了大建中汤对便秘孕妇的疗效和安全性。我们希望我们的研究结果将有助于管理孕妇便秘。
